As part of its previously announced effort to preserve capital, on March 1, 2022, Yumanity Therapeutics, Inc. (the 'Company') entered into a License Agreement (the 'New License') with MIL 40G, LLC ('Licensor') to downsize its corporate headquarters. Under the New License, the Company will pay a monthly license fee of $68,775 for the use of office and laboratory space located at 40 Guest Street in Boston, Massachusetts. The Company also paid a security deposit of $68,775 upon execution of the New License.

The New License commences on April 1, 2022 and will expire on December 31, 2022. The foregoing summary of the New License is not complete and is qualified in its entirety by reference to the full text of the New License filed as Exhibit 10.1 to this Current Report on Form 8-K. In connection with the Company and Licensor entering into the New Lease, on March 1, 2022, the Company and Licensor entered into a Termination of License Agreement (the 'Termination Agreement') to terminate that certain License Agreement, dated as of February 5, 2020, between the Company and Licensor (the 'License'), with such termination to be effective on March 31, 2022. Under the License, the Company currently occupies research and development, laboratory and office space at 40 Guest Street in Boston, Massachusetts.

The initial term of the License was scheduled to expire in April 2023 and provided for rent of $365,550 per month. As consideration for the early termination of the License, the Company will pay $731,100 by forfeiting to Licensor $365,550 of one month's pre-paid rent and an existing security deposit of $365,550 under the License.